Katherine Stueland
Principal executive officer pay for Katherine Stueland, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
GeneDx Holdings Corp. (WGS) FY2023–FY2025
Beat peersTSR 4629% vs peer group 33% over FY2023–FY2025
Turnaround$100 invested moved from behind the peer group ($31.59 vs $104.59) to ahead ($1494.01 vs $138.77) over FY2023–FY2025
Aligned: paid up as stock roseCAP $545,947→$43,351,549 while $100 invested went $31.59→$1494.01
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $3.5M | $545,947 |
| FY2024 | $4.4M | $51.5M |
| FY2025 | $13.5M | $43.4M |
The company's "$100 invested" index ran $31.59 at FY2023 → $1494.01 by FY2025 — an annualized return of 587.7%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 587.7%/yr at WGS ( FY2023–FY2025). See the CEO track-record ranking for context.